China Unveils Ambitious Biomedical Industry Plan for Global Leadership by 2030
The Chinese government has announced a comprehensive five-year plan aimed at transforming the country into a global leader in pharmaceutical innovation. The strategy, outlined through multiple ministries, seeks to increase China's share of globally developed first-in-class drugs to 25% by 2030 and boost annual industry revenue to 3.5 trillion yuan ($520 billion). This includes fostering R&D advancements supported by AI and quantum computing, as well as expanding into next-generation therapies like antibody-drug conjugates (ADCs), cell and gene therapies, CAR-T, and mRNA vaccines. The plan emphasizes innovation-driven growth over scale-based expansion. It also highlights the industrialization of traditional Chinese medicine using modern frameworks. Citi analysts noted that this strategy signals a broad policy push across the pharmaceutical value chain to position China among global leaders by 2030. Recent licensing deals between Western and Chinese biopharma companies have surged, with major partnerships like AstraZeneca's $18.5 billion deal with CSPC in January 2026 underscoring growing collaboration. China currently leads the world in innovative drug pipelines, accounting for one-third of global totals as of late 2025. The government aims to move beyond licensing and into international clinical trials, overseas R&D, manufacturing, and cross-border technology cooperation.
Tickers: $AZN
Topics: China's economic strategy innovation pharmaceuticals R&D